Industry Briefs: Feb. 20, 2012

Company News

Apricus Bioscience’s wholly owned subsidiary NexMed (USA) has signed with Sandoz, a division of Novartis, an exclusive collaboration for Germany to market Apricus Bio’s Vitaros (alprostadil) drug for treating erectile dysfunction. Read More

The Biomedical Advanced Research and Development Authority has awarded a contract worth up to $67 million for the development of a Tetraphase Antibiotic. Read More

Catalent Pharma Solutions has completed the acquisition of the clinical trials supplies business of Aptuit. Read More

FDA issued a Warning Letter to West-Ward Pharmaceticals for significant violations of cGMP regulations for finished pharmaceuticals. Read More

Mylan plans to change the name of its specialty subsidiary from Dey Pharma to Mylan Specialty. Read More

OncoPep has entered an exclusive license agreement with Dana-Farber for therapeutic multipeptide-vaccine technology for hematologic cancers. Read More

Quintiles plans to expand its commercial services in the Middle East and North Africa region through an agreement with Dayarn Pharma. Read More

Wyeth Pharmaceuticals (now part of Pfizer) seeks $960 million in damages from Sun Pharmaceutical for alleged patent infringement. Read More

People News

Amgen has named Michael Severino senior vice-president of global development and corporate chief medical officer. Read More

Astellas has appointed Charlotte M. E. Kremer as senior vice-president of its global medical affairs organization. Read More

Hospira has appointed Zena G. Kaufman as senior vice-president of quality. Read More

OSO BioPharmaceuticals has named Milton Boyer president of manufacturing. Read More

Patheon has appointed Stuart Grant as executive vice-president and chief financial officer. Read More